Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

por Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B., Yamazaki, Naoya, Loquai, Carmen, Robert, Caroline, Flaherty, Keith T.
Publicado 2023

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

por Dummer, Reinhard, Flaherty, Keith T., Robert, Caroline, Arance, Ana, de Groot, Jan Willem B., Garbe, Claus, Gogas, Helen J., Gutzmer, Ralf, Krajsová, Ivana, Liszkay, Gabriella, Loquai, Carmen, Mandalà, Mario, Schadendorf, Dirk, Yamazaki, Naoya, di Pietro, Alessandra, Cantey-Kiser, Jean, Edwards, Michelle, Ascierto, Paolo A.
Publicado 2022